Articles

Ibrutinib Salvage in Relapsed CLL After Allogeneic Transplantation

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Final Results from the CLL20 Study: Alemtuzumab plus Dexamethasone in Very High–Risk Patients with CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Ibrutinib-Based Regimens for Patients with Relapsed/Refractory CLL: Impact of Complex Karyotype

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Frontline Chemoimmunotherapy with Fludarabine/Cyclophosphamide/Rituximab versus Bendamustine/Rituximab in Advanced CLL: Final Analysis of the CLL10 Study

Conference Correspondent

Ibrutinib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Safety and Efficacy of Ibrutinib plus Rituximab in Relapsed Mantle-Cell Lymphoma

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Combination of Ibrutinib and BCL-2 or Spleen Tyrosine Kinase Inhibitors in Ibrutinib-Resistant Diffuse Large B-Cell Lymphoma

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Ibrutinib in Patients with Bortezomib-Refractory Mantle-Cell Lymphoma

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Ibrutinib in Relapsed/Refractory Mantle-Cell Lymphoma: 2-Year Results of Safety and Durability of Response

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

The Role of Hepcidin in Multicentric Castleman Disease

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Page 207 of 329